Yan Bingbing, Xiong Chunqiu, Huang Feifeng, Zhang Mingming, Mo Yan, Bai Hua
Department of Gynecology, The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China.
Medicine (Baltimore). 2020 Jul 2;99(27):e20802. doi: 10.1097/MD.0000000000020802.
It is imperative to further the understanding of the drug resistance mechanisms of ovarian cancer (OC) and to identify useful biological markers for prognosis prediction.Cormine, cBioportal, and The Cancer Genome Atlas databases were used to search microarray data of gene methylation related to OC, drug resistance in OC, and prognosis, and to analyze methylated genes potentially inducing the drug resistance in OC. Fifty-five DNA-methylated genes significantly associated with drug resistance in OC were screened, and the regulatory mechanisms underlying changes in methylation levels of these genes were systematically integrated.Enrichment and annotation of biological processes indicated that most of the above DNA-methylated genes were significantly associated with cell proliferation and cell cycle. In addition, pathway enrichment demonstrated that the above DNA-methylated genes were significantly associated with PI3K-AKT and P53 signaling pathways. Among the 55 genes, 4 were significantly associated with OC prognostic disease-free survival, namely bromodomain containing 4, PDZ domain containing 1 (PDZK1), phosphatase and tensin homolog, and TNF receptor superfamily member 10c; 5 were significantly related to overall survival, namely bromodomain containing 4, PDZK1, PIK3C2B, Rh associated glycoprotein, and DYRK; among them, the degree of methylation of TNF receptor superfamily member 10c, PDZK1, and Rh associated glycoprotein genes was significantly correlated with mRNA expression. Furthermore, PDZK1, Rh associated glycoprotein, and TNF receptor superfamily member 10c genes showed significant hypomethylation in drug-resistance tissues of OC, and their mRNAs had significantly high expression.The association between the methylation of these 55 genes and OC and drug resistance in OC, in addition to bioinformatics analyses clarify the important mechanisms of gene methylation in the development, progression, and drug resistance of OC.
进一步了解卵巢癌(OC)的耐药机制并确定用于预后预测的有用生物标志物势在必行。利用Cormine、cBioportal和癌症基因组图谱数据库搜索与OC、OC耐药性和预后相关的基因甲基化微阵列数据,并分析可能诱导OC耐药性的甲基化基因。筛选出55个与OC耐药性显著相关的DNA甲基化基因,并系统整合这些基因甲基化水平变化的调控机制。生物过程的富集和注释表明,上述大多数DNA甲基化基因与细胞增殖和细胞周期显著相关。此外,通路富集表明上述DNA甲基化基因与PI3K-AKT和P53信号通路显著相关。在这55个基因中,有4个与OC预后无病生存期显著相关,即含溴结构域4、含PDZ结构域1(PDZK1)、磷酸酶和张力蛋白同源物以及肿瘤坏死因子受体超家族成员10c;有5个与总生存期显著相关,即含溴结构域4、PDZK1、PIK3C2B、Rh相关糖蛋白和双特异性酪氨酸磷酸化调节激酶;其中,肿瘤坏死因子受体超家族成员10c、PDZK1和Rh相关糖蛋白基因的甲基化程度与mRNA表达显著相关。此外,PDZK1、Rh相关糖蛋白和肿瘤坏死因子受体超家族成员10c基因在OC耐药组织中表现出显著低甲基化,其mRNA表达显著升高。这55个基因的甲基化与OC及OC耐药性之间的关联,除生物信息学分析外,还阐明了基因甲基化在OC发生、发展和耐药中的重要机制。